DV Trading LLC Buys 399,359 Shares of Compass Therapeutics, Inc. $CMPX

DV Trading LLC increased its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 1,649.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 423,566 shares of the company’s stock after purchasing an additional 399,359 shares during the period. DV Trading LLC owned approximately 0.24% of Compass Therapeutics worth $2,241,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CMPX. M&T Bank Corp bought a new stake in Compass Therapeutics in the 4th quarter worth approximately $4,104,000. Royce & Associates LP bought a new position in shares of Compass Therapeutics during the 4th quarter valued at $1,536,000. Seven Fleet Capital Management LP bought a new position in shares of Compass Therapeutics during the 4th quarter valued at $3,054,000. NEXTBio Capital Management LP bought a new position in shares of Compass Therapeutics during the 4th quarter valued at $5,982,000. Finally, Blue Owl Capital Holdings LP boosted its stake in shares of Compass Therapeutics by 33.8% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,466,525 shares of the company’s stock worth $18,615,000 after buying an additional 875,000 shares during the last quarter. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock opened at $1.91 on Friday. Compass Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $6.88. The company’s fifty day simple moving average is $2.12 and its 200-day simple moving average is $3.99. The stock has a market capitalization of $343.97 million, a PE ratio of -4.66 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). As a group, research analysts anticipate that Compass Therapeutics, Inc. will post -0.42 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on CMPX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a report on Friday, July 17th. Wall Street Zen downgraded Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Citizens Jmp reissued a “market outperform” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Tuesday, April 28th. LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They set a “buy” rating and a $5.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.25.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.